Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections

References

• Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2013. Atlanta: CDC; 2013. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf
   Google Scholar
• Cluck D, Lewis P, Stayer B, et al. Ceftolozane-tazobactam: A new-generation cephalosporin. Am J Health-system Pharm. 2015 Dec 15;72(24):2135–2146.
   PubMed Web of Science ®Google Scholar
• Pham JN, Chambers I, Poirel L, et al. Detection of a plasmid-mediated inducible cephalosporinase DHA-1 from Escherichia coli. Pathol. 2010 Feb;42(2):196–197.
   PubMed Web of Science ®Google Scholar
• Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009 Jan;22(1):161–182. Table of Contents.
   PubMed Web of Science ®Google Scholar
• Takeda S, Nakai T, Wakai Y, et al. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2007 Mar;51(3):826–830.
   PubMed Web of Science ®Google Scholar
• Doi Y, Shibata N, Shibayama K, et al. Characterization of a novel plasmid-mediated cephalosporinase (CMY-9) and its genetic environment in an Escherichia coli clinical isolate. Antimicrob Agents Chemother. 2002 Aug;46(8):2427–2434.
   PubMed Web of Science ®Google Scholar
• Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother. 1992 Apr;29 Suppl A:19–24.
   PubMed Web of Science ®Google Scholar
• Leone M, Albanese J, Garnier F, et al. Risk factors of nosocomial catheter-associated urinary tract infection in a polyvalent intensive care unit. Intensive Care Med. 2003 Jul;29(7):1077–1080.
   PubMed Web of Science ®Google Scholar
• Cek M, Tandogdu Z, Wagenlehner F, et al. Healthcare-associated urinary tract infections in hospitalized urological patients–a global perspective: results from the GPIU studies 2003–2010. World J Urol. 2014 Dec;32(6):1587–1594.
   PubMed Web of Science ®Google Scholar
• Phillips B, Ball C, Sackett D, et al. Oxford centre for evidence-based medicine-levels of evidence (March 2009). Centre for Evidence Based Medicine Web site. Oxford; 1998. Available from: http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/
   Google Scholar
• Grabe M, Bartoletti R, Bjerklund-Johansen TE, et al. Guidelines on urological infections. European Association of Urology (EAU) guidelines presented at 30th annual EAU congress. Madrid: European Association of Urology. 2015.
   Google Scholar
• Database of the US National Library of Medicine (Medline). [cited 2016 Feb 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed.
   Google Scholar
• JustFind. Library System of the JLU Giessen. [cited 2016 Feb 2]. Available from: https://www.uni-giessen.de/ub/en.
   Google Scholar
• Google Scholar web search engine. [cited 2016 Feb 2]. Available from: https://scholar.google.com/.
   Google Scholar
• ResearchGate social networking site for scientists and researchers. [cited 2016 Feb 2]. Available from: https://www.researchgate.net/.
   Google Scholar
• Hoban DJ, Nicolle LE, Hawser S, et al. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2010. Diagn Microbiol Infect Dis. 2011 Aug;70(4):507–511.
   PubMed Web of Science ®Google Scholar
• Török E, Cooke FJ, Moran E. Oxford handbook of infectious diseases and microbiology. Oxford: Oxford University Press; 2009.
   Google Scholar
• Sutton JD, Mynatt RP, Rybak MJ. Ceftazidime-avibactam and ceftolozane-tazobactam: two new beta-lactam/beta-lactamase inhibitor combinations. MAD-ID Newsletter [Internet]. 2014. Spring:4–16 [cited 2016 Feb 23]. Available from: http://textlab.io/doc/888197/mad-newsletter-spring-2014-final---mad-id.
   Google Scholar
• Cubist Pharmaceuticals LLC. Safety and efficacy of IV CXA-101 and IV ceftazidime in patients with complicated urinary tract infections. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2010–2016. Available from: https://ClinicalTrials.gov/show/NCT00921024.
   Google Scholar
• Cubist Pharmaceuticals LLC. Safety and efficacy study to compare IV CXA 101/tazobactam and metronidazole with meropenem in complicated intraabdominal infections. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2010–2016. Available from: https://clinicaltrials.gov/ct2/show/NCT01147640
   Google Scholar
• Cubist Pharmaceuticals LLC. Study comparing the safety and efficacy of intravenous CXA-201 and intravenous levofloxacin in complicated urinary tract infection, including pyelonephritis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2013–2016. Available from: https://ClinicalTrials.gov/show/NCT01345929.
   Google Scholar
• Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/Tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clinical Infect Dis. 2015 May 15;60(10):1462–1471.
   PubMed Web of Science ®Google Scholar
• Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet (London, England). 2015 May 16;385(9981):1949–1956.
   PubMed Web of Science ®Google Scholar
• Armstrong ES, Farrell DJ, Palchak M, et al. In vitro activity of ceftolozane-tazobactam against anaerobic organisms identified during the ASPECT-cIAI study. Antimicrob Agents Chemother. 2016 Jan;60(1):666–668.
   Web of Science ®Google Scholar
• Zerbaxa: EPAR summary of Product Characteristics. 2015 Sep [cited 2016 Feb 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003772/WC500194597.pdf.
   Google Scholar
• Takeda S, Ishii Y, Hatano K, et al. Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2007 Nov;30(5):443–445.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Ge Y, et al. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int J Antimicrob Agents. 2009 Nov;34(5):402–406.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Ge Y. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2010 Sep;65(9):1972–1974.
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Sader HS, Flamm RK, et al. Ceftolozane/tazobactam activity tested against gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents. 2014 Jun;43(6):533–539.
   PubMed Web of Science ®Google Scholar
• Juan C, Zamorano L, Perez JL, et al. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother. 2010 Feb;54(2):846–851.
   PubMed Web of Science ®Google Scholar
• Estabrook M, Bussell B, Clugston SL, et al. In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum beta-lactamases. J Clin Microbiol. 2014 Nov;52(11):4049–4052.
   PubMed Web of Science ®Google Scholar
• Walkty A, Karlowsky JA, Adam H, et al. In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. Antimicrob Agents Chemother. 2013 Nov;57(11):5707–5709.
   PubMed Web of Science ®Google Scholar
• Kuck NA, Jacobus NV, Petersen PJ, et al. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother. 1989 Nov;33(11):1964–1969.
   PubMed Web of Science ®Google Scholar
• Lee J, Oh CE, Choi EH, et al. The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates. Int J Infect Dis. 2013 Aug;17(8):E638–E43.
   Google Scholar
• Yang QW, Zhang H, Wang Y, et al. A 10 year surveillance for antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae in community- and hospital-associated intra-abdominal infections in China. J Med Microbiol. 2013;62:1343–1349.
   PubMed Web of Science ®Google Scholar
• Culver SM, Martens MG. Piperacillin/Tazobactam (ZOSYN). Infect Dis Obstet Gynecol. 1996;4(5):258–262.
   PubMedGoogle Scholar
• Titelman E, Karlsson IM, Ge Y, et al. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis. 2011 May;70(1):137–141.
   PubMed Web of Science ®Google Scholar
• Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010 Jan;23(1):160–201.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/beta-lactamase inhibitor combination. Drugs. 2013 Feb;73(2):159–177.
   PubMed Web of Science ®Google Scholar
• Cho JC, Fiorenza MA, Estrada SJ. Ceftolozane/Tazobactam: A novel cephalosporin/beta-lactamase inhibitor combination. Pharmacother. 2015 Jul;35(7):701–715.
   PubMed Web of Science ®Google Scholar
• Dobrindt U, Hacker J. Uropathogens and virulence factors. In: Naber KG, Scaeffer AJ, Heyns CF, et al. editors. Urogenital infections. Spain: European Association of Urology. 2010. p. 4–23.
   Google Scholar
• Rice LB. Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp Epidemiol. 2010 Nov;31(Suppl 1):S7–10.
   PubMed Web of Science ®Google Scholar
• Sorbera M, Chung E, Ho CW, et al. Ceftolozane/Tazobactam: a new option in the treatment of complicated gram-negative infections. P & T Peer-Rev J Formulary Manage. 2014 Dec;39(12):825–832.
   PubMedGoogle Scholar
• Merck Sharp & Dohme Corp. Zerbaxa (ceftolozane and tazobactam) for injection, forintravenous use. Highlights of Prescribing Information. 2015 [cited 2016 Jan 11]. Available from: http://www.merck.com/product/usa/pi_circulars/z/zerbaxa/zerbaxa_pi.pdf.
   Google Scholar
• Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014 Jan;74(1):31–51.
   PubMed Web of Science ®Google Scholar
• Page MG. Emerging cephalosporins. Expert Opin Emerg Drugs. 2007 Nov;12(4):511–524.
   PubMed Web of Science ®Google Scholar
• Sucher AJ, Chahine EB, Cogan P, et al. Ceftolozane/Tazobactam: a new cephalosporin and beta-lactamase inhibitor combination. Ann Pharmacother. 2015 Sep;49(9):1046–1056.
   PubMed Web of Science ®Google Scholar
• Goo KS, Sim TS. Designing new beta-lactams: implications from their targets, resistance factors and synthesizing enzymes. Curr Comput Aided Drug Des. 2011 Mar;7(1):53–80.
   PubMed Web of Science ®Google Scholar
• Moyá B, Zamorano L, Juan C, et al. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010 Sep;54(9):3933–3937.
   PubMed Web of Science ®Google Scholar
• Perletti G, Magri V, Wagenlehner FME, et al. CXA-101 cephalosporin antibiotic. Drugs Future. 2010 Dec;35(12):977–986.
   Web of Science ®Google Scholar
• Zhanel GG, Sniezek G, Schweizer F, et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant staphylococcus aureus. Drugs. 2009;69(7):809–831.
   PubMed Web of Science ®Google Scholar
• Craig WA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother. 2013 Apr;57(4):1577–1582.
   PubMed Web of Science ®Google Scholar
• Toda A, Ohki H, Yamanaka T, et al. Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4849–4852.
   PubMed Web of Science ®Google Scholar
• Pillar C. Mode of action of CXA-101 based on minimum bactericidal concentration (MBC) analysis and timekill kinetic (TK) analysis. In: 48th annual ICAAC/IDSA 46th annual meeting: a joint meeting of the American Society for Microbiology and the Infectious Diseases Society of America; 2008 Oct 25–28. Washington (DC): IDSA; 2008.
   Google Scholar
• Scott LJ. Ceftolozane/Tazobactam: a review in complicated intra-abdominal and urinary tract infections. Drugs. 2016 Feb;76(2):231–242.
   PubMed Web of Science ®Google Scholar
• Lepak AJ, Reda A, Marchillo K, et al. Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother. 2014 Oct;58(10):6311–6314.
   PubMed Web of Science ®Google Scholar
• Bulik CC, Christensen H, Nicolau DP. In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. Antimicrob Agents Chemother. 2010 Jan;54(1):557–559.
   PubMed Web of Science ®Google Scholar
• Vanscoy B, Mendes RE, McCauley J, et al. Pharmacological basis of beta-lactamase inhibitor therapeutics: tazobactam in combination with ceftolozane. Antimicrob Agents Chemother. 2013 Dec;57(12):5924–5930.
   PubMed Web of Science ®Google Scholar
• Soon RL, Lenhard JR, Bulman ZP, et al. Combinatorial pharmacodynamics of ceftolozane-tazobactam against genotypically defined beta-lactamase-producing escherichia coli: Insights into the pharmacokinetics/pharmacodynamics of beta-lactam-beta-lactamase inhibitor combinations. Antimicrob Agents Chemother. 2016 Apr;60(4):1967–1973.
   PubMed Web of Science ®Google Scholar
• Ge Y, Whitehouse MJ, Friedland I, et al. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob Agents Chemother. 2010 Aug;54(8):3427–3431.
   PubMed Web of Science ®Google Scholar
• Miller B, Hershberger E, Benziger D, et al. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother. 2012 Jun;56(6):3086–3091.
   PubMed Web of Science ®Google Scholar
• Chandorkar G, Xiao A, Mouksassi MS, et al. Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections. J Clin Pharmacol. 2015 Feb;55(2):230–239.
   PubMed Web of Science ®Google Scholar
• Wooley M, Miller B, Krishna G, et al. Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam. Antimicrob Agents Chemother. 2014;58(4):2249–2255.
   PubMed Web of Science ®Google Scholar
• Halstenson CE, Wong MO, Johnson CA, et al. Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment. J Clin Pharmacol. 1994 Dec;34(12):1208–1217.
   PubMed Web of Science ®Google Scholar
• Umeh O, Cebrik D, Friedland I. A double-blind, randomized, phase 2 study to compare the safety and efficacy of intravenous CXA-101 and intravenous ceftazidime in complicated urinary tract infection. 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010); 2010 Sep 12–15; Boston (MA); 2010.
   Google Scholar
• Golan Y. Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options. BMC Infect Dis. 2015;15:313.
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp. Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014) In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2016. Available from: https://clinicaltrials.gov/show/NCT02728089.
   Google Scholar
• EPAR Summary of the risk management plan (RMP) for Zerbaxa (ceftolozane /tazobactam). 2015 Aug [cited 2016 Feb 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Risk-management-plan_summary/human/003772/WC500190191.pdf.
   Google Scholar
• Merck Sharp & Dohme Corp. Merck Completes Tender Offer to Acquire Cubist. 2015 Jan 21, [cited 2016 Feb 25]. Available from: http://www.mercknewsroom.com/news-release/corporate-news/merck-completes-tender-offer-acquire-cubist.
   Google Scholar
• Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon. 2003 Feb;49(2):53–70.
   PubMed Web of Science ®Google Scholar
• Sundqvist M, Kahlmeter G. Complicated and healthcare associated urinary tract infections: aetiology and antimicrobial resistance. In: Naber KG, Scaeffer AJ, Heyns CF, et al. editors. Urogenital infections. Spain: European Association of Urology; 2010. p. 82–92.
   Google Scholar
• Oteo J, Perez-Vazquez M, Campos J. Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010 Aug;23(4):320–326.
   PubMed Web of Science ®Google Scholar
• Cassier P, Lallechere S, Aho S, et al. Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M beta-lactamase-producing Escherichia coli: a case-control study in a French teaching hospital. Clin Microbiol Infect. 2011 Nov;17(11):1746–1751.
   PubMed Web of Science ®Google Scholar
• Gyssens IC. Antibiotic policy. Int J Antimicrob Agents. 2011 Dec;38 Suppl:11–20.
   PubMed Web of Science ®Google Scholar